Bioxytran

Bioxytran has entered into a Sponsored Research Agreement with the University of Minnesota to advance its carbohydrate-based technology platform. This collaboration is expected to strengthen its scientific foundation and support the evolution of its research and development pipeline, potentially leading to new therapeutic and diagnostic applications.

Bioxytran has entered into a commercial Distribution Agreement with Khoury Medical LTD for its A-SUQAR dietary supplement. This agreement marks a significant milestone for Bioxytran, transitioning it from a development-stage organization to one with recurring commercial revenue. It also validates their proprietary carbohydrate-based galectin platform.

Bioxytran has initiated a research collaboration with the University of Georgia to evaluate its lead drug candidate, PHM23, for blocking the Influenza A virus subtype H5N1 bird flu virus. This collaboration, supported by a $100 million grant, could lead to a breakthrough in antiviral treatments and significantly enhance Bioxytran's market position and stock value.

Bioxytran announced positive Phase 2 clinical trial results for its drug Bioxytran===ProLectin-M, showing complete elimination of viral load in 100% of treated subjects by Day 7. This positive outcome is expected to significantly boost the company's stock price and reputation, paving the way for late-stage clinical development and regulatory discussions.